search tools

AMP Study Explores Potency of Antibodies to Combat HIV Infection (Rutgers University)

Edit Public Technologies 15 Sep 2016
(Source. Rutgers University). Rutgers' New Jersey Medical School's Clinical Research Center (NJMS-CRC) is participating as a clinical trial site in a novel study that could signal a new way of protecting people from developing HIV infection, the virus that causes AIDS ... Photo. LaCarla Donaldson ... The study is a joint venture of the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) ... (noodl. 35367230) ....

GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update (GeoVax Labs Inc)

Edit Public Technologies 05 Aug 2016
McNally continued, 'we announced in June the filing of an Investigational New Drug (IND) application with the FDA for the next human clinical trial (HVTN 114) of our preventive HIV vaccine, GOVX-B11. HVTN 114 will be conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID)....

GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update

Edit Stockhouse 05 Aug 2016
McNally continued, "we announced in June the filing of an Investigational New Drug (IND) application with the FDA for the next human clinical trial (HVTN 114) of our preventive HIV vaccine, GOVX-B11. HVTN 114 will be conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID)....

GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced ...

Edit Stockhouse 02 Aug 2016
With NIAID's support, GOVX-B11 has been tested at various doses and regimens by the HIV Vaccine Trials Network (HVTN) in trials involving approximately 500 participants where it has shown excellent safety and reproducible immunogenicity ... A phase 1 trial (HVTN 114) will first evaluate the effect of late boosts (gp120 protein and the GeoVax MVA vaccine) in individuals previously vaccinated with GOVX-B11....

GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials (GeoVax Labs Inc)

Edit Public Technologies 02 Aug 2016
With NIAID's support, GOVX-B11 has been tested at various doses and regimens by the HIV Vaccine Trials Network (HVTN) in trials involving approximately 500 participants where it has shown excellent safety and reproducible immunogenicity ... A phase 1 trial (HVTN 114) will first evaluate the effect of late boosts (gp120 protein and the GeoVax MVA vaccine) in individuals previously vaccinated with GOVX-B11....

#AIDS2016: Study may produce HIV vaccine in 10 years

Edit Independent online (SA) 20 Jul 2016
HVTN 702 trial, which would enrol 5 400 HIV-negative South African men and women, is “pivotal” to the future of vaccine research ... ....

No Vaccine in Sight for HIV/AIDS, Scientists Say

Edit Voa News 20 Jul 2016
Scientists attending the 21st International AIDS Conference in Durban say there is still no vaccine in sight to prevent HIV/AIDS infections ... Although no specific vaccine has become the sole hope, scientists are vigorously pursuing tests and trials called HVTN 702. The vaccine being tested was developed from a trial in Thailand several years ago, and showed a modest degree of effectiveness ... ....

Early HIV vaccine results lead to major trial: researchers

Edit Modern Ghana 19 Jul 2016
By AFP. New HIV infections have plateaued for the past 10 years after a steep dip from a peak rate of 3.3 million in 1997, said the authors of a comprehensive analysis in The Lancet HIV journal. By Alexander Joe (AFP/File) ... "We hope to have results in five years, and it is going to be a very exciting five years for all of us because it is the result of many, many years of hard work," said Glenda Gray, HVTN Africa programme director ... ....

>Early HIV vaccine results lead to major trial: researchers

Edit Modern Ghana 19 Jul 2016
By AFP. New HIV infections have plateaued for the past 10 years after a steep dip from a peak rate of 3.3 million in 1997, said the authors of a comprehensive analysis in The Lancet HIV journal. By Alexander Joe (AFP/File) ... "We hope to have results in five years, and it is going to be a very exciting five years for all of us because it is the result of many, many years of hard work," said Glenda Gray, HVTN Africa programme director ... ....

Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV (Inovio Pharmaceuticals Inc)

Edit Public Technologies 14 Jul 2016
(Source. Inovio Pharmaceuticals Inc). Funding for Potential Breakthrough Therapy is Part of Prestigious NIH/Delany Grant for Industry-Academic Collaboration. PLYMOUTH MEETING, Pa., July 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc ... Dr ... PENNVAX-GP is Inovio's lead preventive and therapeutic immunotherapy for HIV and is being evaluated in a phase I clinical study (HVTN-098) involving 94 healthy subjects as a preventive vaccine....

GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial (GeoVax Labs Inc)

Edit Public Technologies 30 Jun 2016
The IND was filed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.The Phase 1 trial (designated HVTN 114) will be conducted by the NIAID-supported HIV Vaccine Trials Network (HVTN). The Company expects HVTN 114 to begin enrolling patients in September 2016 ... About HVTN ... Support for the HVTN comes from NIAID ... For more information, go to www.hvtn.org....

GeoVax Developing Vaccine to Treat Chronic Hepatitis B Infection (GeoVax Labs Inc)

Edit Public Technologies 06 Jun 2016
(Source. GeoVax Labs Inc). Expansion of Company's Pipeline of MVA-VLP Vaccines. GeoVax Labs, Inc. (OTCQB ... There is a clear medical need to treat Hepatitis B infections, which affect millions of people around the world ... About GeoVax ... Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID)....

GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge (GeoVax Labs Inc)

Edit Public Technologies 01 Jun 2016
(Source. GeoVax Labs Inc). Single Dose Provided 100% Protection,. Tetravalent Hemorrhagic Fever Virus Vaccine under Development. GeoVax Labs, Inc. (OTCQB ... VLPs mimic a natural infection, triggering the body to produce a robust and durable immune response with both antibodies and T cells ... Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with NIAID funding ... (noodl....
×
×
×
×